Yellowstone Biosciences Appoints Dr. Ita O'Kelly as COO

Yellowstone Biosciences, a pioneering biotech company renowned for its work on soluble bispecific T-cell receptor therapies targeting the HLA Class II in oncology, has announced the appointment of Dr. Ita O’Kelly as the new Chief Operating Officer. With an impressive track record spanning nearly a decade in the biotech industry, O’Kelly transitions from her role as Executive Director at Immunocore to spearhead Yellowstone’s leadership team. Her extensive experience in product management and strategic development in soluble TCR therapeutics aligns well with Yellowstone's mission to innovate treatments for acute myeloid leukaemia (AML) and other cancers. Founded as a spin-out from the University of Oxford and funded by Syncona Limited, the company is anchored on transformative research spearheaded by its co-founder, Professor Paresh Vyas, who has significantly advanced the understanding of HLA Class II in therapeutic contexts. This strategic executive appointment signifies Yellowstone's commitment to advancing its promising pipeline to clinical stages and propelling significant corporate growth.